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Abstract 
Background: Gender disparities in the management of dysglycaemia, defined as either impaired glucose toler-
ance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent data 
from two nationwide cohorts of patients suggested no gender difference as regards the risk for diabetes-related CV 
complications but indicated the presence of a gender disparity in risk factor management. The aim of this study was 
to investigate gender differences in screening for dysglycaemia, cardiovascular risk factor management and prognosis 
in dysglycemic CAD patients.
Methods: The study population (n = 16,259; 4077 women) included 7998 patients from the ESC-EORP EUROASPIRE 
IV (EAIV: 2012–2013, 79 centres in 24 countries) and 8261 patients from the ESC-EORP EUROASPIRE V (EAV: 2016–2017, 
131 centres in 27 countries) cross-sectional surveys. In each centre, patients were investigated with standardised 
methods by centrally trained staff and those without known diabetes were offered an oral glucose tolerance test 
(OGTT). The first of CV death or hospitalisation for non-fatal myocardial infarction, stroke, heart failure or revasculariza-
tion served as endpoint. Median follow-up time was 1.7 years. The association between gender and time to the occur-
rence of the endpoint was evaluated using Cox survival modelling, adjusting for age.
Results: Known diabetes was more common among women (32.9%) than men (28.4%, p < 0.0001). OGTT (n = 8655) 
disclosed IGT in 17.2% of women vs. 15.1% of men (p = 0.004) and diabetes in 13.4% of women vs. 14.6% of men 
(p = 0.078). In both known diabetes and newly detected dysglycaemia groups, women were older, with higher 
proportions of hypertension, dyslipidaemia and obesity. HbA1c was higher in women with known diabetes. Recom-
mended targets of physical activity, blood pressure and cholesterol were achieved by significantly lower proportions 
of women than men. Women with known diabetes had higher risk for the endpoint than men (age-adjusted HR 1.22; 
95% CI 1.04–1.43).
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Background
Dysglycaemia, defined as the presence of either 
impaired glucose tolerance (IGT) or type 2 diabetes 
(T2DM), represents a major cause of morbidity and 
mortality worldwide, mainly due to its high risk of vas-
cular complications, including coronary artery disease 
(CAD) [1, 2]. International guidelines recommend both 
screening for glucose perturbations and a comprehen-
sive cardiovascular (CV) risk factor control in people 
with dysglycaemia and CAD [3]. However, real-world 
data show that guideline adherence is poor and in need 
of considerable improvement [4, 5].
The presence of gender disparities in the manage-
ment of dysglycaemia in CAD patients is a serious 
medical challenge [6–8]. First of all, despite men aver-
agely receiving a diagnosis of dysglycaemia at a younger 
age, cardiometabolic risk factors seem to escalate to a 
greater extent in women as they proceed from normo- 
to dysglycaemia [9–11]. Secondly, although male sex is 
associated with a higher absolute risk of CAD several 
studies reported on an excess relative risk of diabetes-
associated CAD in women [8, 11–13]. Historically, this 
has been considered to be due to both the attenuating 
effect of diabetes on the cardiometabolic protection 
conferred by oestrogens [14] and to the fact that that 
women, being treated less effectively than men, are less 
likely to achieve recommended risk factor targets [15, 
16]. More recent data from two nationwide cohorts of 
patients with atherosclerotic disease manifestations 
partially revisited these assumptions, suggesting no dif-
ference between women and men as regards the risk for 
diabetes-related CV complications, but confirming the 
existence of a gender disparity in risk factor manage-
ment [17, 18]. The results of such studies are, however, 
partly conflicting and may be diverse among various 
populations [19]. One reason is that these observations 
were made based on registry-derived information i.e. 
not on standardised investigations, which in itself may 
cause bias, and another that these populations were 
domestic.
The main objective of the present study is to investi-
gate gender differences in screening for dysglycaemia, 
CV risk factor management in a large homogene-
ous cohort of dysglycemic patients with verified CAD 
subjected to a standardised examination within the 
framework of the European Action on Secondary and 
Primary Prevention by Intervention to Reduce Events 
(EUROASPIRE) IV and V [20, 21]. A secondary objec-
tive was to report CV outcomes in relation to gender.
Methods
Study population
The study population (n = 16,259; 4077 women) consists 
of 7998 patients from the ESC-EORP EUROASPIRE IV 
(EAIV: 2012–2013, 79 centres in 24 countries) and 8261 
patients from the ESC-EORP EUROASPIRE V (EAV: 
2016–2017, 131 centres in 27 countries) cohorts. Details 
on the participating countries and centres are presented 
as appended information (see Additional file 1: Appendix 
S1).
Consecutively diagnosed CAD patients, 18 to 80 years 
old, were identified from diagnostic registers, hospital 
discharge lists or other sources. They had to be hospital-
ised for an elective or emergency coronary artery bypass 
grafting (CABG), an elective or emergency percutaneous 
coronary intervention (PCI), an acute myocardial infarc-
tion (MI) (ICD-10 I21) or acute myocardial ischemia 
(ICD-10 I20) three (EUROASPIRE IV) or two years 
(EUROASPIRE V) to six months prior to the date of the 
study visit. Extensive information was collected by means 
of standardized interviews and investigations by cen-
trally trained research staff, using standardized methods 
and with uniform equipment. Data were electronically 
submitted to the data management centre (EURObser-
vational Research Programme (EORP), ESC, Sophia-
Antipolis, France).
Methods
Major efforts were implemented in standardizing all 
measurements used in the participating centres, includ-
ing central training of observers.
Height (cm) and weight (kg) were recorded in light 
indoor clothes without shoes (Scales 701 and Measuring 
stick model 220; SECA Medical Measuring Systems and 
Scales, Birmingham, U.K.).
Waist circumference was measured with the patient 
standing, using a metal tape applied horizontally at the 
point midway in the midaxillary line between the lowest 
rim of the ribcage and the superior iliac crest.
Blood pressure Systolic and diastolic blood pressure 
was measured twice on the right upper arm in the sitting 
position using an automatic digital sphygmomanometer 
(Omron M6; OMRON Corporation, Kyoto, Japan). The 
mean of both measurements was used for the analyses.
Conclusions: Guideline-recommended risk factor control is poorer in dysglycemic women than men. This may con-
tribute to the worse prognosis in CAD women with known diabetes.
Keywords: Diabetes, Coronary artery disease, Gender, Impaired glucose tolerance, Prevention
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Laboratory investigations Venous blood was drawn 
after ≥ 10 h of fasting for measuring serum total and high 
density lipoprotein-cholesterol (HDL-C), triglycerides, 
and glycated haemoglobin A1c (HbA1c) while low den-
sity cholesterol- cholesterol (LDL-C) was calculated by 
Friedewald’s formula [22]. Samples were stored locally 
at − 70  °C and subsequently sent to a central laboratory 
for final storage and analyses (Disease Risk Unit, National 
Institute for Health and Welfare, Helsinki, Finland) 
accredited by the Finnish Accreditation Service, fulfilling 
the requirements of the standard SFS-EN International 
Organization for Standardization/International Electro-
technical Commission 17,025:2005. Total and HDL-C 
and triglycerides were analysed on a clinical chemistry 
analyser (Abbot Architect Analyzer; Abbott Labora-
tories, Abbott Park, IL) using an enzymatic method for 
measuring total cholesterol. HbA1c was measured with 
an immunoturbidimetric International Federation of 
Clinical Chemistry and Laboratory Medicine aligned 
method (Abbot Architect Analyzer) in fasting venous 
whole blood sampled in an EDTA tube.
All patients without known diabetes were offered 
an Oral Glucose Tolerance test (OGTT; 75  g glucose 
in 200  mL water). Plasma glucose (PG) was analysed 
locally in the fasting state (FPG) and 2  h after the glu-
cose load (2  h-PG) with a photometric point-of-care 
technique (Glucose 201 + (EAIV) or Glucose 201RT 
(EAV); HemoCue, Ängelholm, Sweden) [23]. Since the 
HemoCue technique is cholesterol-sensitive, glucose val-
ues were corrected for cholesterol according to the for-
mula: HemoCue glucose + 0.15 x (total cholesterol − 5). 
HemoCue automatically converts the venous blood glu-
cose to plasma glucose by using the International Fed-
eration of Clinical Chemistry and Laboratory Medicine 
(IFCC) recommendation: plasma glucose = 1.11 × whole 
blood glucose [24].
Pharmacological treatment: Information on medica-
tion intake was based on the self-reported use at the time 
of the interview.
Definitions
Educational level was defined as “low” if the patient 
reported no further education than completed primary 
school.
Smoking was defined as self-reported smoking and/or 
a breath carbon monoxide higher than 10 ppm by means 
of Smokerlyzer (Bedfont Scientific, Model Micro1) at 
the time of interview. Persistent smoking was defined 
as smoking at the time of interview among those who 
smoked the month prior to the index event.
Overweight was defined as a Body Mass Index (BMI) 
between 25 and 29.9 kg/m2 and obesity as BMI ≥ 30 kg/
m2. Central obesity was defined as a waist circumference 
≥ 88 cm for women and ≥ 102 cm for men.
The physical activity target was defined by the question: 
“Do you take regular physical activity for at least 30 min 
on average five times a week?’’.
The use of four cardioprotective drugs, consisting of 
antiplatelet drugs, beta-blockers, renin–angiotensin–
aldosterone system (RAAS) blockers, and lipid-lowering 
drugs was assessed at the interview visit.
Treatment target attainment was assessed for blood 
pressure and LDL-C according to the 2012 European 
Guidelines on Cardiovascular Disease Prevention in clin-
ical practice [25] and the 2013 European Guidelines for 
Diabetes, Pre-Diabetes and Cardiovascular Disease [26].
Glycaemic state was defined according to World Health 
Organization as outlined in Additional file  1: Table  S1 
[27].
Previously known diabetes is defined as a self-reported 
history of diabetes or use of any glucose-lowering 
medication.
Newly detected dysglycaemia is defined as the presence 
of IGT or T2DM according to the OGTT, performed in 
patients without previously known diabetes.
Anxiety and depression scores were estimated by means 
of the Hospital Anxiety and Depression Scale (HADS) 
questionnaire [28].
Generic health status was assessed by means of VAS-
scale of the EuroQoL 5D questionnaire, varying from 0 
(the worst possible health status) to 100 (the best possible 
health status) [29].
Follow‑up
All centres were asked to complete a follow-up ques-
tionnaire for the EUROASPIRE IV and V participants. 
To be eligible for the follow-up part the retrieved infor-
mation had to cover ≥ 12 months follow-up on ≥ 90% of 
the patients from the participating centres. Fatal events 
were recorded as death from the following causes: CAD, 
stroke, other vascular, cancer, other causes and unknown. 
Nonfatal events were recorded as hospitalisation for PCI, 
CABG, acute MI, stroke/transient ischemic attack, and 
heart failure. Follow-up information was obtained from 
patient interviews, medical records, or external regis-
tries or databases (mortality registries, local records and 
archives) or, if needed, by contacting relatives or a family 
physician.
The first of CV death or hospitalisation for any of the 
following non-fatal events: MI, non-fatal stroke, heart 
failure, CABG or PCI served as the endpoint, and time at 
risk for developing the endpoint was calculated from the 
baseline study visit. In the absence of an event, time at 
risk was censored at the last date of follow-up.
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Ethics
Local Ethics Committees approval was obtained via the 
National Coordinators for each participating country 
in both surveys. Signed informed consent was obtained 
from each participant and stored locally in the patient 
file.
Statistical analysis
Distributions of baseline characteristics were summa-
rized according to means, standard deviations and pro-
portions. Characteristics of women and men, both in 
the previously known T2DM group and in the newly 
detected dysglycaemia group, were compared by using 
the Mann–Whitney U-test for continuous variables and 
Fisher’s exact test for categorical variables. The associa-
tion between gender and time to the occurrence of the 
endpoint was evaluated using Cox survival modelling, 
adjusting for age. The assumption of proportionality of 
hazards in women and men in time, was checked by fit-
ting a gender-by-time interaction term in the model. A 
double-sided type I error level of α = 0.05 was used to 
indicate statistical significance. All data analyses were 
undertaken using SAS statistical software (release 9.4) 
at the Department of Public Health and Primary Care, 
Ghent University, Belgium.
Role of the founding source
The EUROASPIRE IV and V surveys were performed 
under the auspices of the European Society of Cardiology, 
EURObservational Research Programme. The sponsors 
of the EUROASPIRE surveys (detailed in the Funding 
section) had no role in the design, data collection, data 
analysis, data interpretation, decision to publish, or writ-
ing the manuscript.
Results
Of the 16,259 patients 4077 (25.1%) were women (Fig. 1). 
A total of 4796 (29.5%) had previously known diabe-
tes (women 32.9%; men 28.4%; p < 0.0001), whereof 97% 
T2DM. An OGTT was performed in 8655 (80%) of the 
remaining 11,463 patients. The proportion of women 
and men who did not undergo such screening did not 
differ (p = 0.26). The final study population of dysglyce-
mic individuals with CAD comprised 4796 patients with 
previously known T2DM and 4029 with newly detected 
dysglycaemia.
Glycaemic state and screening for glucose perturbations
In the study population whose glycaemic status was 
known, equal proportions of women (21.8%) and 
men (23.8%; p = 0.55 after age adjustment) were 
Fig. 1 Flowchart of the patients and their glycaemic classification according to the oral glucose tolerance test (OGTT). The dysglycemic study 
population is highlighted with yellow background. EA EUROASPIRE, IFG impaired fasting glucose, IGT impaired glucose tolerance, T2DM type 2 
diabetes mellitus
Page 5 of 12Ferrannini et al. Cardiovasc Diabetol           (2021) 20:38  
normoglycaemic, while the proportion of IGT was signif-
icantly higher among women (17.2%) than men (15.1%; 
p = 0.015) and that of impaired fasting glucose (IFG) 
lower in women than men (p < 0.0001) (Fig.  2). Slightly 
more men were newly diagnosed with T2DM (women 
13.4% vs. men 14.6%; p = 0.020).
Screening for dysglycaemia based on FPG, 2  h-PG 
and HbA1c values (alone or in combination) showed 
that more women (66.5%) than men (59.9%) (p < 0.0001) 
would not have been identified as dysglycemic without 
the 2 h-PG value (Fig. 3). Only 4.5% of women and 4.4% 
of men were identified as dysglycaemic simultaneously by 
all three tests.
Clinical characteristics (Table 1)
Women were older than men, had a lower educational 
level, and had a higher frequency of hypertension, 
dyslipidaemia and obesity in both glycaemic categories.
Renal function, expressed as eGFR, was better in 
women than in men. Total cholesterol and LDL-C lev-
els were significantly higher (p < 0.0001) in women than 
Fig. 2 The distribution of glycaemic state divided by gender in the study population. IFG impaired fasting glucose, IGT impaired glucose tolerance, 
T2DM type 2 diabetes mellitus
Fig. 3 Proportions and their overlap between screening with different methods [FPG ≥ 7 mmol/L, 2hPG mmol/L ≥ 7.8 mmol/L, HbA1c ≥ 6.5% 
(48 mmol/mol)] and their combinations in men and women with newly detected dysglycaemia (IGT or T2DM). 2 h-PG 2-h post-load glucose, FPG 
fasting plasma glucose, HbA1c glycated haemoglobin, IGT impaired glucose tolerance, T2DM type 2 diabetes mellitus
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Table 1 Baseline characteristics according to gender and glycaemic category
Previously known diabetes Newly detected dysglycaemia
Women (n = 1342) Men (n = 3454) P‑value Women (n = 1049) Men (n = 2980) P‑valuea
Age (years) 66.6 (8.7) 64.6 (8.9) < 0.0001 66.8 (8.9) 64.0 (9.6) < 0.0001
Low educational level 24.5 (324/1323) 16.1 (548/3401) < 0.0001 19.9 (208/1046) 15.4 (456/2960) 0.0010
Currently smoking 16.1 (216/1342) 29.0 (1002/3454) < 0.0001 22.1 (232/1049) 33.1 (987/2980) < 0.0001
Persistent smoking 53.7 (116/216) 53.0 (531/1002) 0.88 48.3 (112/232) 44.9 (443/987) 0.38
Physical activity level on target 45.8 (594/1297) 55.2 (1852/3358) < 0.0001 51.5 (528/1026) 57.0 (1665/2922) 0.0024
Medical history
 Hypertension 87.2 (1158/1328) 79.5 (2712/3410) < 0.0001 80.8 (841/1041) 73.7 (2172/2947) < 0.0001
 Dyslipidaemia 78.4 (1011/1289) 75.0 (2496/3327) 0.016 75.0 (766/1021) 68.9 (1977/2869) 0.00023
Anthropometrics—vitals
 BMI (kg/m2) 31.6 (5.9) 30.1 (4.8) 0.0001 29.8 (5.5) 29.0 (4.3) 0.0023
 Obesity 57.7 (754/1306) 45.6 (1550/3396) 0.0001 43.9 (460/1048) 36.6 (1089/2977) < 0.0001
 Central obesity 86.7 (1080/1246) 63.6 (2077/3266) < 0.0001 77.3 (789/1021) 54.2 (1577/2909) < 0.0001
 SBP (mmHg) 138.3 (20.3) 137.2 (18.9) 0.18 134.4 (19.5) 134.2 (18.6) 0.99
 DBP (mmHg) 79.3 (11.6) 80.1 (11.0) 0.036 79.3 (11.3) 80.3 (11.0) 0.0011
 Heart rate (bpm) 70.9 (11.2) 68.8 (11.1) < 0.0001 69.1 (11.1) 67.9 (11.4) 0.0018
Laboratory central assessment
 LDL-C (mmol/L) 2.52 (1.04) 2.21 (0.90) < 0.0001 2.76 (1.08) 2.46 (0.91) < 0.0001
 HDL-C (mmol/L) 1.15 (0.31) 1.03 (0.26) < 0.0001 1.29 (0.31) 1.12 (0.26) < 0.0001
 Total C (mmol/L) 4.56 (1.38) 4.08 (1.14) < 0.0001 4.74 (1.22) 4.31 (1.10) < 0.0001
 Triglycerides (mmol/L) 1.99 (1.66) 1.91 (1.56) 0.0005 1.55 (0.81) 1.62 (1.05) 0.83
 FPG (mmol/L) n.a n.a n.a 6.53 (0.97) 6.63 (1.08) 0.0072
 2 h-PG (mmol/L) n.a n.a n.a 9.81 (2.37) 9.65 (2.51) 0.070
 HbA1c (NGSP, %)—(IFCC, mmol/mol)b 7.36 (1.70)—57 7.07 (1.49)—54 < 0.0001 5.80 (0.46)—40 5.79 (0.56)—40 0.014
 Creatinine (µmol/L) 85.3 (53.7) 97.9 (53.2) < 0.0001 78.0 (28.5) 93.4 (37.5) < 0.0001
 eGFR (mL/min/1.73 m2) 89.2 (24.5) 76.9 (21.2) < 0.0001 93.9 (20.2) 78.5 (18.1) < 0.0001
Pharmacological treatment
 RAAS blockers 80.5 (1070/1329) 79.7 (2723/3418) 0.55 72.8 (759/1042) 76.0 (2251/2963) 0.046
 Beta blockers 85.7 (1138/1328) 83.7 (2860/3419) 0.084 83.3 (869/1043) 82.5 (2444/2964) 0.54
 Antiaggregants 93.7 (1242/1325) 93.1 (3184/3419) 0.48 91.3 (952/1043) 92.6 (2747/2965) 0.16
 Lipid lowering 83.7 (1112/1329) 87.6 (2991/3414) 0.00046 83.2 (866/1041) 85.7 (2540/2963) 0.055
 Statins 82.5 (1097/1329) 86.5 (2952/3414) 0.00071 82.1 (855/1041) 85.0 (2519/2963) 0.030
 Ezetimibe 3.1 (41/1329) 3.1 (105/3419) 1.00 2.2 (23/1043) 2.5 (75/2966) 0.64
 All four above 58.6 (775/1323) 58.9 (2009/3413) 0.87 52.0 (541/1040) 55.0 (1628/2960) 0.10
 Diuretics 48.2 (640/1329) 41.5 (1420/3418) < 0.0001 37.2 (388/1042) 29.3 (869/2964) < 0.0001
 Glucose-lowering drugs 92.7 (1244/1342) 91.6 (3162/3451) 0.24 n.a n.a n.a
 Antidepressant/antianxiety drugs 9.6 (128/1330) 7.1 (224/3418) 0.004 9.8 (102/1042) 5.2 (155/2963) < 0.0001
Advice on lifestyle changes
 Stop smoking 83.7 (169/202) 86.2 (833/966) 0.38 84.9 (191/225) 84.5 (792/937) 1.00
 Healthy diet 91.2 (1105/1212) 89.4 (2849/3186) 0.093 83.6 (806/964) 85.8 (2347/2734) 0.10
 Weight loss 72.8 (929/1276) 74.0 (2463/3327) 0.41 63.9 (647/1012) 67.4 (1953/2898) 0.049
 Increase physical activity 59.7 (762/1277) 65.6 (2176/3315) 0.00018 58.8 (597/1016) 63.3 (1821/2879) 0.012
Actions taken to change lifestyle
 Stop smoking 79.7 (165/207) 76.0 (728/958) 0.28 85.8 (193/225) 82.0 (769/938) 0.20
 Healthy diet 89.9 (1064/1183) 89.1 (2809/3152) 0.47 90.1 (858/952) 89.0 (2385/2679) 0.36
 Weight loss 58.8 (741/1260) 61.3 (2021/3299) 0.14 58.0 (583/1006) 60.1 (1720/2861) 0.23
 Increase physical activity 25.0 (301/1203) 33.5 (1065/3183) < 0.0001 32.3 (307/ 951) 40.2 (1100/2738) < 0.0001
 Attended a CPRP 27.0 (355/1315) 33.7 (1147/3404) < 0.0001 32.1 (332/1035) 35.7 (1052/2943) 0.034
 Attended a DEP 25.8 (314/1217) 26.0 (809/3116) 0.94 n.a n.a n.a
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in men, both in patients with previously known T2DM 
and among those with newly detected dysglycaemia. 
Serum triglycerides were significantly higher in women 
than in men in those with previously known T2DM. The 
glycaemic control as assessed by HbA1c was less strict 
in women than in men with known T2DM (p < 0.0001) 
(Table  1); in women HbA1c < 7% (53  mmol/mol) was 
51.0% and in men 57.3% (p < 0.0001).
Microvascular complications were significantly more 
common in women than among men with previously 
known T2DM: retinopathy (25.0% vs. 15.8%; p < 0.0001), 
renal involvement (4.8% vs. 3.2%; p = 0.03) and neuropa-
thy (23.5% vs. 14.9%; p < 0.0001).
Lifestyle habits (Table 1)
Less women than men were current smokers, but the 
proportion of persistent smokers (patients who were 
smoking at the time of the recruiting event and still 
smoking at interview) was similar in both genders across 
the two glycaemic categories. Less women than men 
had been advised on and increased their physical activ-
ity. Significantly less women than men attended a Car-
diac Prevention and Rehabilitation Programme in both 
glycaemic categories, but there was no gender differ-
ence in the attendance at a Diabetes Educational Pro-
gramme in patients with previously known T2DM. The 
scores expressing quality of life, i.e., EuroQoL 5D and 
HeartQoL, were significantly lower in women than men. 
Women in both glycaemic categories were prescribed 
significantly more antidepressant/antianxiety drugs than 
men.
Pharmacological treatment and targets attainment
The proportion of patients taking each of four cardiopro-
tective drug classes and their combination did not differ 
according to gender in the two glycaemic categories, with 
the exception of RAAS blockers that were prescribed 
less frequently to women than men with newly detected 
dysglycaemia (72.8% vs. 76.0%; p = 0.046) and lipid-low-
ering therapy prescribed less frequently to women than 
men with previously known T2DM (83.7% vs. 87.6%; 
p = 0.00046) (Table  1). The combination of all four car-
dioprotective drugs was prescribed to < 60% of patients, 
with no significant differences between genders. Com-
pared with men, women with known T2DM were more 
frequently prescribed insulin (33% vs. 25.2%; p < 0.0001) 
while smaller proportions of women used metformin 
(53.2% vs. 58.9%; p < 0.001).
The proportion of men and women reaching differ-
ent blood pressure and LDL-C targets is shown in Fig. 4. 
Among patients with previously known T2DM more 
women than men had blood pressure ≥ 150/100 mmHg 
(27.7% vs. 23.5%; p < 0.0034) and LDL-C ≥ 3.0  mmol/L 
(23.6% vs. 15.6%; p < 0.0001) whereas they achieved an 
LDL-C level < 1.8  mmol/L in a significantly lower pro-
portion (26.1%; vs. men 35.5%; p < 0.0001). A similar 
pattern was observed in patients with newly diagnosed 
dysglycaemia with women having a higher propor-
tion of LDL-C ≥ 3.0  mmol/L and a lower proportion of 
LDL-C < 1.8 mmol/L.
CV events during follow‑up
The median follow-up time was 1.7  years, and the 
number of events in patients with newly detected dys-
glycaemia were 105 in women and 340 in men. The cor-
responding numbers in patients with known T2DM 
Cell entries are % (n/total number) or mean (SD)
Italic values indicate statistically significant p-values
2 h-PG 2-h post-load glucose, BMI Body Mass Index, CPRP Cardiac Prevention and Rehabilitation Programme, DBP diastolic blood pressure, DEP diabetes educational 
programme, eGFR estimated glomerular filtration rate, EQ-5D EuroQol 5D Questionnaire, FG fasting plasma glucose, HbA1c glycated haemoglobin, HDL-C high density 
lipoprotein cholesterol, Heart QoL Heart Quality of Life, IFCC International Federation of Clinical Chemistry, LDL-C low-density lipoprotein cholesterol, NGSP National 
Glycohemoglobin Standardization Program, RAAS renin–angiotensin–aldosterone system, SBP systolic blood pressure, T2DM type 2 diabetes mellitus, Total C total 
cholesterol, VAS visual analogue scale
a significance level for testing differences between men and women in each diagnostic group
b mean HbA1c levels were converted using the NGSP calculator at http://www.ngsp.org/conve rt1.asp
Table 1 (continued)
Previously known diabetes Newly detected dysglycaemia
Women (n = 1342) Men (n = 3454) P‑value Women (n = 1049) Men (n = 2980) P‑valuea
Quality of life assessment
 EQ-5D VAS score 56.1 (26.3) 60.6 (27.5) < 0.0001 59.2 (27.1) 63.4 (27.7) < 0.0001
 HeartQoL Global score 1.79 (0.72) 2.14 (0.67) < 0.0001 1.97 (0.70) 2.27 (0.62) < 0.0001
 HeartQoL Physical score 1.81 (0.74) 2.17 (0.70) < 0.0001 2.00 (0.72) 2.31 (0.64) < 0.0001
 HeartQoL Emotional score 1.73 (0.78) 2.08 (0.72) < 0.0001 1.91 (0.77) 2.18 (0.69) < 0.0001
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were 233 and 500 respectively. A detailed description 
of the events is given in Additional file 1: Table S2. The 
total number of observed person-years was 23,703. The 
age-adjusted incidence of the study endpoint was signifi-
cantly higher in women than in men with known T2DM 
(125.4 vs. 100.8/1000 person-years) with a hazard ratio 
(95% confidence interval (CI); p-value) of women vs. men 
of 1.22 (1.04–1.43; p = 0.015). There was no significant 
gender difference in the age-adjusted incidence of the 
endpoint in patients with newly detected dysglycaemia 
(women vs. men: incidence 65.9 vs. 75.4/1000 person-
years), with a hazard ratio of 0.86 (95% CI 0.69–1.08; 
p = 0.19).
Discussion
The main finding of the present study is that women with 
CAD and dysglycaemia, compared with men, are more 
burdened with CV risk factors, less often participate in 
cardiac rehabilitation, report less physical activity and 
less often achieve satisfactory risk factor control—all 
important factors for preventing further glucose deterio-
ration and future CV events. Other important findings 
are the significantly higher prevalence of microvascular 
complications seen among women and that a majority 
of women (67%) and large part of men (60%) would not 
have been identified as dysglycaemic without an OGTT.
The EUROASPIRE surveys were developed to deter-
mine how the European guidelines on CV disease 
prevention are implemented in a real-world setting. The 
Guidelines on Diabetes, Pre-diabetes and Cardiovascu-
lar Diseases, first issued in 2003 and recently updated 
in 2019, reinforced the importance of a multi-targeted 
approach to CV risk factors [3]. There is a substan-
tial need for a general improvement in detection and 
treatment of dysglycaemia [4]. Attention to glycae-
mic perturbations in women has been advocated in the 
gynaecologic field with regard to the polycystic ovary 
syndrome, premature menopause, gestational diabetes 
and pre-eclampsia [7]. The present study underlines the 
importance of widening this attention to women with 
dysglycaemia and CAD, most of them post-menopausal.
Screening for glucose perturbations
Appropriate screening for glucose metabolism pertur-
bations is of particular importance in women, since it 
appears that the advantage given by their later CAD 
presentation compared with men is eliminated by the 
presence of diabetes [7, 13]. The DECODE (Diabetes 
Epidemiology: Collaborative analysis Of Diagnostic cri-
teria in Europe) study showed that the hazard ratios for 
CV mortality was higher in women than men with newly 
diagnosed diabetes compared with their normogly-
caemic counterparts [30]. Indeed, in our population of 
patients burdened by CAD, a significantly higher propor-
tion of women had previously known T2DM, in keeping 
with the Euro Heart Survey in 2007 [8]. Further, more 
a b
Fig. 4 Proportion of patients with previously known T2DM and newly detected dysglycaemia reaching different blood pressure (a) and LDL-C (b) 
targets in the total cohort
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women than men were identified as dysglycemic due to 
a higher proportion of IGT, as in the population-based 
DECODE study [30]. Importantly, IGT is a pre-diabetes 
state prognostically as unfavourable as newly detected 
T2DM, and only detectable by means of an OGTT [31, 
32]. The higher prevalence of IGT in women with estab-
lished CAD compared with men has not been previously 
reported. This finding underlines the importance of using 
the OGTT in both women and men with CAD, rather 
than relying on a fasting glucose only, unless it already 
indicates the presence of diabetes (≥ 7.0  mmol/l) and 
understanding that HbA1c is an even less reliable screen-
ing test [31].
Pharmacological and lifestyle management of CV risk 
factors
In order to avoid conclusions based on blood pressure 
and LDL-C levels just above the recommended treatment 
targets, we presented proportions at different levels (see 
Fig. 4).
Even taking these less strict targets into considera-
tion, target attainment remains poor. Considering that 
contemporary guidelines recommend even stricter cut-
offs for blood pressure (< 130/80  mmHg) and LDL-C 
(< 1.4  mmol/L) in all CAD patients [3] than those rec-
ommended at the time for EUROASPIRE IV and V, the 
present findings must be considered markedly disadvan-
tageous for the future prognosis of women with CAD and 
dysglycaemia. A German population study showed that 
women with T2DM and CVD were more likely to have 
blood pressure, LDL-C and HbA1c uncontrolled com-
pared with men [16], as was also reported from more 
than 8000 Croatian T2DM patients [33]. The SWEDE-
HEART registry has consistently reported that less 
women than men reached the blood pressure and LDL-C 
targets one year after an acute MI [34]. This seems to 
apply to ethnically and socioeconomically heterogeneous 
cohorts, as a study on CAD patients (32% T2DM) con-
ducted in 11 countries reported that all pharmacological 
and lifestyle targets were achieved by a significantly lower 
proportion of women than men [35].
HbA1c in women with previously known T2DM was 
higher than in men, despite glucose-lowering drugs being 
prescribed in similar proportions [33]. It has been specu-
lated that females with T2DM are more exposed to meta-
bolic disturbances than males [7, 36], but this does not 
offset the fact that the risk factor intervention is less well 
implemented among the women.
The only favorable lifestyle-related aspect for women 
was that they smoked less than men. Otherwise, women 
achieved the desired physical activity target and attended 
cardiac prevention and rehabilitation programs in lower 
proportions than men. That their quality of life was 
lower and that they were more often prescribed antide-
pressants and antianxiety drugs compared with men is 
in accordance with the finding that a cluster of CV risk 
factors including low levels of physical activity, anxiety, 
depression and unhealthy lifestyles was more common 
in women [37]. Moreover, despite being advised on and 
having pursued weight loss in similar proportions, obe-
sity remained significantly more prevalent among women 
than men, especially in those with previously known 
T2DM, in whom the central obesity was very common 
(86.7%). Finally, as discussed in a recent editorial, women 
and men might have different preferences, compliance 
and response to lifestyle management, an area in need of 
further research [38].
CV outcomes
The finding of a poorer prognosis in CAD women with 
known T2DM is in line with their less well managed risk 
factor control. A recent Danish study reported that the 
relative rates of CV complications associated with T2DM 
were higher in women than men in all ages [18] and also 
seen in a large British study where only incident cases, i.e. 
patients with recently diagnosed T2DM, were included 
[17]. Although there may be analytical discrepancies to 
account for when discussing these studies, the main mes-
sage seems to be that women with dysglycaemia are more 
exposed to CV complications than men, not the least 
since they are less well treated. Thus, early screening of 
CAD women in order to detect dysglycaemia at an early 
stage and with sensitive methods should be encouraged. 
This is particularly important considering their higher 
prevalence of microvascular complications, which at least 
partially may explain their worse outcome. That micro-
vascular disease is more prevalent in post-menopausal 
women than men underlines the need to address this in 
risk stratification of CAD patients by non-invasive meas-
ures such as spot albuminuria and cardiac autonomic 
neuropathy, in addition to OGTT [11, 39–41].
Strengths and limitations
Our study has several strengths. First, the EUROASPIRE 
surveys report data from a large cohort of dysglycemic 
patients with CAD, providing a comprehensive picture 
of their management. All data derived from standard-
ized interviews, measurements and central laboratory 
assessments, made by centrally trained staff. To obtain 
a large population of women and allow comparisons 
between genders, we merged the EUROASPIRE IV 
and EUROASPIRE V surveys, which applied the same 
research methods and reported similar results about the 
secondary prevention of CAD in dysglycemic patients [4, 
42].
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Some limitations have to be accounted for. First, there 
may be a selection bias. CAD patients who were unwill-
ing to participate were probably sicker than the par-
ticipants. Therefore, it may be assumed that the present 
data, if anything, represent an overestimate of the qual-
ity of care, which is discouraging considering the far 
from optimal risk factor control reported, especially in 
women. Additionally, it would have been of interest to 
assess subsequent total mortality in relation to the qual-
ity of risk factor management and preventive treatments, 
but due to the rather short follow-up time the number of 
events was too low for total mortality to be considered 
as an endpoint. It may be argued that the proportion of 
women (approximately 25%) of all CAD cases was low 
although the total number of women was large (4077 of 
whom 2391 were dysglycaemic). We did, however, aim 
at recruiting a representative sample of CAD patients. 
With the given age restriction the proportion of women 
reflects the situation in the real-life clinical practice.
Conclusions
Screening for dysglycaemia in CAD, which is still gen-
erally poorly performed across countries included in 
the EUROASPIRE surveys, is of special importance for 
women who carry a heavier burden of glucose pertur-
bations and whose glycaemic control is poorer than in 
men. CV risk factor management by means of pharmaco-
logical and lifestyle interventions is significantly less well 
implemented in dysglycemic women with CAD, and as a 
consequence women with known T2DM and established 
CAD have a worse prognosis compared with men.
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